Coherus Oncology (CHRS) EBIAT (2016 - 2025)
Historic EBIAT for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to -$44.5 million.
- Coherus Oncology's EBIAT rose 647.49% to -$44.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $394.5 million, marking a year-over-year increase of 59791.61%. This contributed to the annual value of $28.5 million for FY2024, which is 11198.32% up from last year.
- According to the latest figures from Q3 2025, Coherus Oncology's EBIAT is -$44.5 million, which was up 647.49% from $297.8 million recorded in Q2 2025.
- Over the past 5 years, Coherus Oncology's EBIAT peaked at $297.8 million during Q2 2025, and registered a low of -$172.9 million during Q1 2021.
- For the 5-year period, Coherus Oncology's EBIAT averaged around -$22.2 million, with its median value being -$47.6 million (2024).
- Per our database at Business Quant, Coherus Oncology's EBIAT tumbled by 58618.86% in 2021 and then skyrocketed by 64286.52% in 2025.
- Coherus Oncology's EBIAT (Quarter) stood at -$45.7 million in 2021, then decreased by 28.75% to -$58.9 million in 2022, then plummeted by 35.3% to -$79.7 million in 2023, then soared by 348.34% to $197.8 million in 2024, then plummeted by 122.51% to -$44.5 million in 2025.
- Its EBIAT stands at -$44.5 million for Q3 2025, versus $297.8 million for Q2 2025 and -$56.6 million for Q1 2025.